Literature DB >> 27508034

Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head.

Ming-Yue Xiong1, Li-Qiang Liu1, Shi-Qiong Liu1, Zhen-Hui Liu1, Hang-Fei Gao1.   

Abstract

Avascular necrosis of femoral head (AVFH) is a clinically recalcitrant disease of hip that leads to joint destruction. Osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B (RANK) and RANK ligand (RANKL) regulates the balance, maturation and function of osteoclast and bone remodeling. This study aims to investigate molecular pathways which leads to AVN by studying expression profile of OPG, RANK and RANKL genes. Quantitative Real Time-PCR is used to evaluate mRNA expression of OPG, RANK and RANKL. mRNA and protein level in normal and necrotic tissue from 42 samples of ANFH specimens were analyzed. OPG and RANKL protein levels are estimated by western blotting. The results indicated that OPG mRNA levels are higher but not significantly different in necrotic tissue than that in normal tissue (P>0.05). Although expression of RANK and RANKL is significantly lower than that of OPG, RANK and RANKL mRNA levels are higher in necrotic tissue than normal tissue (P<0.05). Protein levels of OPG and RANKL show no significant difference. In conclusion, OPG, RANK and RANKL play important role in progress of bone remodeling in necrotic area and in disturbance of bone homeostasis, which might have an effect on bone destruction and subsequent collapse of hip joint.

Entities:  

Keywords:  Avascular necrosis of the femoral head; RANK; RANKL; gene expression; osteopretegerin

Year:  2016        PMID: 27508034      PMCID: PMC4969450     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  27 in total

1.  The 677C-->T mutation of the methylene-tetrahydrofolate reductase gene in the pathogenesis of osteonecrosis of the femoral head.

Authors:  Charalampos G Zalavras; Konstantinos N Malizos; Eleni Dokou; George Vartholomatos
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 3.  Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.

Authors:  Paul J Kostenuik
Journal:  Curr Opin Pharmacol       Date:  2005-09-26       Impact factor: 5.547

4.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.

Authors:  A E Hughes; S H Ralston; J Marken; C Bell; H MacPherson; R G Wallace; W van Hul; M P Whyte; K Nakatsuka; L Hovy; D M Anderson
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

Review 5.  RANKL-RANK signaling in osteoclastogenesis and bone disease.

Authors:  Teiji Wada; Tomoki Nakashima; Nishina Hiroshi; Josef M Penninger
Journal:  Trends Mol Med       Date:  2005-12-13       Impact factor: 11.951

6.  Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease.

Authors:  M P Whyte; B G Mills; W R Reinus; M N Podgornik; G D Roodman; F H Gannon; M C Eddy; W H McAlister
Journal:  J Bone Miner Res       Date:  2000-12       Impact factor: 6.741

7.  Hypofibrinolysis, thrombophilia, osteonecrosis.

Authors:  C J Glueck; R A Freiberg; R N Fontaine; T Tracy; P Wang
Journal:  Clin Orthop Relat Res       Date:  2001-05       Impact factor: 4.176

Review 8.  Bone morphogenetic proteins in vascular calcification.

Authors:  Keith A Hruska; Suresh Mathew; Georges Saab
Journal:  Circ Res       Date:  2005-07-22       Impact factor: 17.367

9.  Bone morphogenetic proteins (BMPs) expression in the femoral heads of patients with avascular necrosis.

Authors:  Stavroula Samara; Zoe Dailiana; Sokratis Varitimidis; Christos Chassanidis; Theodora Koromila; Konstantinos N Malizos; Panagoula Kollia
Journal:  Mol Biol Rep       Date:  2013-05-07       Impact factor: 2.316

10.  Pathogenesis of glucocorticoid-induced avascular necrosis: A microarray analysis of gene expression in vitro.

Authors:  Yanyan Bian; Wenwei Qian; Hongling Li; Robert Chunhua Zhao; Wang Xing Shan; Xisheng Weng
Journal:  Int J Mol Med       Date:  2015-07-06       Impact factor: 4.101

View more
  6 in total

1.  Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.

Authors:  Lysann Michaela Kroschwald; Josephine Tabea Tauer; Sonja Ingrid Kroschwald; Meinolf Suttorp; Anne Wiedenfeld; Stefan Beissert; Andrea Bauer; Martina Rauner
Journal:  Oncol Lett       Date:  2019-06-21       Impact factor: 2.967

2.  CORR Insights®: Free Vascularized Fibular Grafting Improves Vascularity Compared With Core Decompression in Femoral Head Osteonecrosis: A Randomized Clinical Trial.

Authors:  Anton Plakseychuk
Journal:  Clin Orthop Relat Res       Date:  2017-06-22       Impact factor: 4.176

3.  Co-Variation of Serum Osteoprotegerin and Pigment-Epithelial Derived Factor as Biomarker of Pancreatic Cancer.

Authors:  M Edderkaoui; C Chheda; A Lim; S J Pandol; R Murali
Journal:  Austin J Gastroenterol       Date:  2022-01-19

4.  Protective Effects of Vitamin K Compounds on the Proteomic Profile of Osteoblasts under Oxidative Stress Conditions.

Authors:  Marta Muszyńska; Ewa Ambrożewicz; Agnieszka Gęgotek; Grzegorz Grynkiewicz; Elżbieta Skrzydlewska
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

5.  Peripheral Blood-Derived Stem Cells for the Treatment of Cartilage Injuries: A Systematic Review.

Authors:  Yanlin Zhu; Weili Fu
Journal:  Front Bioeng Biotechnol       Date:  2022-07-22

Review 6.  Bone Regeneration, Reconstruction and Use of Osteogenic Cells; from Basic Knowledge, Animal Models to Clinical Trials.

Authors:  Greg Hutchings; Lisa Moncrieff; Claudia Dompe; Krzysztof Janowicz; Rafał Sibiak; Artur Bryja; Maurycy Jankowski; Paul Mozdziak; Dorota Bukowska; Paweł Antosik; Jamil A Shibli; Marta Dyszkiewicz-Konwińska; Małgorzata Bruska; Bartosz Kempisty; Hanna Piotrowska-Kempisty
Journal:  J Clin Med       Date:  2020-01-04       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.